trending Market Intelligence /marketintelligence/en/news-insights/trending/bmmsitxxsenprslbv8ivyq2 content esgSubNav
In This List

Healthcare companies tweak FY'18 outlooks; hospitals embracing telehealth

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Healthcare companies tweak FY'18 outlooks; hospitals embracing telehealth

Here are the editors' top picks for the week ended June 1.

Healthcare companies adjust FY'18 outlooks after Q1 results

Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Co. and Bayer AG were among the healthcare companies who adjusted either revenue or earnings forecasts for 2018 after the first quarter to reflect anticipated performance growth or decline.

Convenience, cost savings drive hospitals' interest in telehealth

More hospitals and health systems are allowing patients to see a doctor from their homes instead of going to overcrowded emergency rooms with conditions such as the flu — a practice known as telehealth.

Ga. hospitals experiment with telemedicine to ease critical care shortage

A group of hospitals in the state is using video conferencing and remote monitoring of vital signs to treat intensive care patients — all the way from Australia.

Right-to-try author: Law was intended to 'diminish the FDA's power'

A newly enacted law granting Americans the right to bypass the U.S. Food and Drug Administration's process for seeking access to experimental drugs was meant to loosen the agency's authority, not embolden it, the senator who authored the legislation said.

FDA eases way for generic drug risk programs, thwarting pharma gaming tactics

The U.S. FDA is making it easier for generic drug manufacturers to create their own risk programs in an effort to thwart a blocking tactic used by brand-name companies to forestall competition.

Trump: Expect voluntary 'massive drops' in drug prices, new health plans

President Donald Trump said he has a commitment from some of the nation's largest drugmakers to voluntarily reduce the prices of their medicines. He said the administration plans to give more details in a couple of weeks.

Ebola cases could reach 300; health authorities consider five pipeline drugs

The World Health Organization expects that there will be 100 to 300 cases of Ebola virus in the current outbreak and is preparing five experimental drugs for use, officials said at a press conference in Geneva.

NIH bioethicists weigh in as murder case raises data privacy questions

The recent Golden State Killer arrest raised questions about rights to genetic data, especially for companies such as 23andMe Inc. and Ancestry.com DNA LLC. Now, bioethicists from the U.S.'s National Institutes of Health are weighing in on the budding debate.

Capitol Checkup: Azar to testify; FDA internet summit; opioid, biodefense bills

Health and Human Services Secretary Alex Azar has been summoned to Capitol Hill to explain how President Trump plans to lower drug prices, and U.S. FDA Commissioner Scott Gottlieb plans to hold an internet summit.

Sun Pharma specialty business to propel FY'19 revenue as 'new engine of growth'

Sun Pharmaceutical Industries Ltd. expects low double-digit percentage growth in revenue for fiscal 2019, helped by the launch of several specialty drugs and potential regulatory clearance for its Halol plant.

White House: HHS, FDA chiefs not accountable if right to try fails to save lives

If the promise that the right-to-try legislation would save lives fails to be borne out, HHS Secretary Alex Azar and FDA Commissioner Scott Gottlieb cannot be blamed, a top White House official said.